Blood and cerebrospinal fluid biomarkers for Alzheimer’s disease

Simone Lista, Henrik Zetterberg, Sid E. O’Bryant, Kaj Blennow, Harald Hampel

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In general, a biomarker denes a biological process or disease characteristic that is objectively measured (Biomarkers Denitions Working Group, 2001). Such measurements may be used for diagnostic purposes, but also to study physiological or pathophysiological mechanisms and to evaluate desired pharmacodynamic eects or side eects of pharmacological treatments. According to Biomarkers Denitions Working Group: ‘Molecular and Biochemical Markers of Alzheimer’s Disease’, the ideal biomarker for Alzheimer’s disease (AD) should detect a fundamental feature of neuropathology and be validated in neuropathologically con-rmed cases as well as have a diagnostic accuracy of at least 80% (e Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and National Institute on Aging Working Group, 1998). With respect to clinically relevant questions, such as detection, diagnosis, prediction and treatment of a given disease, biomarkers may serve certain distinct functions (Hampel et al., 2010b; Hampel and Lista, 2013), which are detailed in Table 51.1.

Original languageEnglish
Title of host publicationDementia, Fifth Edition
PublisherCRC Press
Pages528-538
Number of pages11
ISBN (Electronic)9781498703116
ISBN (Print)9781498703123
DOIs
StatePublished - 1 Jan 2017

Fingerprint Dive into the research topics of 'Blood and cerebrospinal fluid biomarkers for Alzheimer’s disease'. Together they form a unique fingerprint.

  • Cite this

    Lista, S., Zetterberg, H., O’Bryant, S. E., Blennow, K., & Hampel, H. (2017). Blood and cerebrospinal fluid biomarkers for Alzheimer’s disease. In Dementia, Fifth Edition (pp. 528-538). CRC Press. https://doi.org/10.1201/9781315381572